tions conducted with small numbers of patients used wild-type and often crudely prepared viral isolates, and it was not until the 1990s that the era of genetic engineering of viruses to enhance their oncolytic potential began. The first reported 3 genetically engineered OV was based on herpes simplex virus type 1 (HSV1). This development was rapidly followed by many studies 2 illustrating the effectiveness of this approach using a diverse range of viruses and tumor models. The main focus of the field during the early development of OVs was to identify viruses or their engineered variants with tumor-selective replication. However, it has always been appreciated that an immune component is important and may be critical for the therapeutic efficacy of this approach. Indeed, OVs are now broadly considered as immunotherapy agents for which effectiveness in patients depends on activation of host antitumor immune responses. [4] [5] [6] Early clinical trials [7] [8] [9] of OVs showed encouraging safety profiles, even at high doses, with some promising responses, evidence of intratumoral viral replication, and immune cell infiltrates. The field is now gaining traction after the report of significant benefits in a large randomized phase 3 clinical trial of the engineered immunostimulatory OV talimogene laherparepvec in patients with advanced melanoma [10] [11] [12] and its subsequent approval in the United
States and European Union. Many OVs are now under investigation in advanced trials, with some encouraging data. 13 Thus, after 2 decades of clinical trials in humans with cancer, OVs are emerging as therapeutic agents in oncology. This review summarizes recent progress in this area and describes ongoing clinical trials.
Mechanisms of OV Action
A general mechanistic understanding of OV action is emerging in which therapeutic efficacy is achieved by a combination of selective tumor cell killing and establishment of antitumor immunity ( Figure) . Immune stimulation is caused by release of cell debris and viral antigens in the tumor microenvironment. Tumor selectivity in OV therapy is driven by several factors. The first of these is cellular entry via virus-specific, receptor-mediated mechanisms. A specific viral entry receptor is often highly expressed on tumor cells. However, there are also efforts to improve tumor selectivity by retargeting OVs to enter cells through tumor-specific receptors. Second, rapid cell division in tumor cells with high metabolic and replicative activity may support increased viral replication compared with normal quiescent cells. In addition, tumor-driver mutations specifically increase the selectivity of virus replication in tumor cells. 14, 15 Third, many tumor cells have deficiencies in antiviral type I interferon signaling, therefore supporting selective virus replication. 16 Viral replication within the tumor microenvironment leads to innate and adaptive immune activation. This activation limits virus spread; however, the presence of virus together with cell lysis, with release of tumor antigens and danger-associated molecular patterns, may overcome immunosuppression in the tumor microenvironment and promote antitumor immunity. The success of this approach is influenced by factors including pre-existing antiviral and antitumor immunity and incorporation of immune stimulatory transgenes.
OVs as Cancer Therapeutics

General Properties
A wide range of viruses with diverse properties are under investigation clinically (eTable 1 in the Supplement). Oncolytic viruses range in size and complexity from large, double-stranded DNA viruses such as vaccinia (190 kilobase [kb]) 17 and HSV1 (152 kb) 18 to the tiny parvovirus H1 (5-kb linear, single-stranded DNA). 19 Oncolytic viruses cause cell lysis by various means during their life cycle, with the exception of retrovirus, which can be rendered lytic by toxic transgene expression. 20 There are a few wild-type viruses in clinical use. These include reovirus, a human virus with low pathogenicity 21, 22 ; coxsackievirus, which is structurally related to polio virus and causes several symptoms in humans 23, 24 ; and viruses with nonhuman hosts, including Newcastle disease virus (avian), 25 parvovirus H1 (rat), 19 and vesicular stomatitis virus (VSV) (insects, horses, cows, and pigs). 
T-cell receptor Cytokine and IFN receptor PAMPs and DAMPs
It is thought that most oncolytic viruses function through a combination of tumor cell lysis and stimulation of innate and adaptive immunity through presentation of viral and tumor antigens. DAMPs indicates damage-associated molecular patterns; IFN, interferon; JAK-STAT, Janus kinase-signal transducer and activator of transcription; MYD 88, myeloid differentiation primary response gene 88; NFKβ, nuclear factor κB; NK, natural killer; PAMPs, pathogen-associated molecular patterns; RF, Interferon regulatory factor; and TRIF, TIR (toll/II-1 receptor)-domain-containing adapter-inducing interferon-β.
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Oncolytic Viruses in Cancer Treatment
Oncolytic vaccinia and measles are derived from vaccine strains. 27 There are documented cases 28 of wild-type measles viruses infections and tumor regression. Most measles OVs are based on the attenuated Edmonston measles vaccine strain (MVEdm), which has an excellent safety record after decades of use in humans.
29
Each type of OV has a specific cellular entry mechanism (eTable 1intheSupplement), which can affect the efficacy. For example, polio virus enters cells through CD155 (the polio virus receptor), which is abundantly expressed in many tumor types. 30 The adenovirus entry receptor, CAR (coxsackie and adenovirus receptor), is expressed variably in tumor cells; therefore, adenovirus retargeting to other cellular receptors to enhance tumor cell binding has also been widely investigated. Table 1 .
Herpesvirus
Oncolytic viruses derived from engineered HSV1 (oHSVs) have been tested widely in patients. A major focus of the field has now moved to talimogene laherparepvec, an immunostimulatory oHSV that expresses granulocyte-macrophage colony-stimulating factor (GM-CSF). 55 Intratumoral injection of talimogene laherparepvec led to significant improvement in durable response rate (DRR) in patients with melanoma (16.3%) compared with controls (2.1%). Effects were most pronounced in patients with stage IIIB, IIIC, IVM1a, or treatment-naive disease. 10, 11 Tumor regression was seen in distant noninjected lesions, suggesting the establishment of systemic antitumor immunity. Talimogene laherparepvec is derived from a clinical HSV1 strain (JS1) deleted for ICP34.5 and ICP47, which normally acts to block HSV1 major histocompatibility class I antigen presentation on the infected cell surface resulting in immune evasion.
56
The reason for the success of this agent is likely a combination of the choice of melanoma (an immunogenic tumor) and immunostimulation via GM-CSF as well as the use of a clinical HSV1 strain backbone, which may allow improved replication in patients compared with other oHSVs built on a laboratory HSV1 strain background.
Adenovirus
Oncolytic adenoviruses were some of the earliest OVs to enter clinical trials. The history of adenovirus as an oncolytic agent has been well reviewed. 57 An E1A/E1B-deleted virus (ONYX015) has been extensively tested and approved for treatment of head and neck cancer in China under the name H101. 58 An integrin-binding retargeted adenovirus, Δ24RGD (DNX2401), has been examined in clinical trials 42, 59 in which the maximum tolerated dose (MTD) was not reached and some responses were observed. Trials are also under way with enadenotucirev, which is built on the Ad11/3 serotype rather than the common Ad5 serotype, rendering it less susceptible to rapid neutralization in the bloodstream.
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Vaccinia Virus
At the present time, JX-594 (Pexa-Vec) is being tested in multiple tumor types. 47 
Polio Virus
Polio virus has demonstrated oncolytic properties in preclinical studies 66 and has attracted attention owing to initial results in brain tumors and wide media exposure. These studies were performed using PVS-RIPO, which has been engineered to abolish the neurovirulence Murine leukemia virus; insertion of yeast cytosine deaminase
None reported
Abbreviations: CT, computed tomography; DRR, durable response rate; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSV, herpes simplex virus; IFNβ, interferon β; IRES, internal ribosome entry site; MTD, maximum tolerated dose; PET, positron emission tomography; PSA, prostate-specific antigen; PTD, protein transduction domain;
RGD, arginine-glycine-aspartate; UTR, untranslated region; VSV, vesicular stomatitis virus.
a The clinical trials listed are not exhaustive but provide representative examples of published studies or the most advanced studies published so far.
Clinical Review & Education Review
Oncolytic Viruses in Cancer Treatment of the native virus. PVS-RIPO is a cytotoxic and immunostimulatory virus with preliminary reports of durable radiographic and clinical responses in glioblastoma. 67 Based on recent phase 1 data, PVS-RIPO was designated as a breakthrough therapy in recurrent glioblastoma.
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Retrovirus
Retroviruses are potentially useful agents because they readily infect mitotic cells and rapidly spread, although without necessarily causing cell lysis. 20 Toca511 is based on murine leukemia virus engineered to express the yeast enzyme cytosine deaminase, which converts 5-fluorocytosine to the toxic metabolite 5-fluorouracil. In studies 53,54 of mice with implanted gliomas, Toca511 therapy resulted in long-term survival and systemic antitumor immunity mediated by memory T cells. Toca511 is currently in a phase 2/3 clinical trial for malignant glioma and has shown promising interim results.
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Reovirus
Reovirus usually produces mild symptoms in humans and can readily enter human cells and activate innate and adaptive immune systems. 21, 22 Oncolytic reovirus is marketed as Reolysin and has been examined in clinical trials alone and in combinations in a range of cancers. 70 Reolysin was given orphan drug status for the treatment of malignant glioma by the FDA in 2015.
Parvovirus H1
Parvovirus H1 causes tumor-selective cell killing that is thought to result from a combination of toxic effects of the viral gene product NS1 as well as lytic viral replication. 19 A trial of wild-type parvovirus H1 (ParvOryx) in recurrent glioblastoma has been completed and this agent is currently in trials for metastatic pancreatic cancer.
Vesicular Stomatitis Virus
Vesicular stomatitis virus selectivity is dependent on deficient interferon signaling. 26, 71 An engineered VSV variant overexpressing interferon β is currently in a clinical trial for liver cancer. It is thought that interferon β may act synergistically with VSV by protecting normal cells from infection and causing tumor cell-specific destruction and antitumor immune responses.
Newcastle Disease Virus
Wild-type Newcastle disease virus has oncolytic effects in a variety of tumor types through syncytia formation and apoptosis. 25 Early clinical trials showed promise and safety 72 ; however, to our knowledge, no trials involving this virus are presently recruiting patients.
Considerations for OV Clinical Trials
With the emergence of increasing numbers of OVs and combinatorial studies in the clinical trial arena, it is worth considering issues involved in clinical trial design and execution. Areas evolving as the field develops are delivery, viral pharmacokinetics and pharmacodynamics, and biomarkers.
Safety
Although mortality has been reported occasionally, published trial data have not shown significant general safety issues. However, as OVs with greater potency are developed and used in novel combinations, safety remains a concern. Despite engineering for tumor cell specificity, there is the possibility of off-target effects, and genetic manipulation may result in unexpected toxic effects. Other concerns include virus mutation, evolution, and recombination; cytotoxic gene products; and viral transmissibility. Oncolytic HSVs have retained their native thymidine kinase gene, which facilitates virus replication and is also the target of the antiviral drug ganciclovir. The retention of thymidine kinase allows the possibility of controlling infection and is seen as an important advantage in terms of safety. Potential safety concerns are reflected in clinical trial criteria, which do not allow inclusion of immunocompromised patients or those with active viral infections.
Toxic and Adverse Effects
Local delivery of OVs is generally well tolerated. The most common adverse effects reported are mild flulike symptoms, which may be more severe after systemic administration, and local reaction at the injection site. These reactions can be reduced by acetaminophen administration before treatment.
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Dose
In contrast to results in conventional drug clinical trials, many OVs do not reach an MTD owing to the concentration of virus stock that is possible to achieve or very high tolerance for the virus. Maximum tolerated dose may need to be re-established for trials using novel therapeutic combinations.
Viral Pharmacokinetics, Pharmacodynamics, and Biomarkers
Effectiveness of OV therapy is monitored by standard approaches, including imaging and tumor-specific biomarkers. In addition, viral pharmacokinetics and pharmacodynamics (shedding, viremia, replication, genomes, and viral load) are frequently included in OV trials. These approaches allow inpatient tracking of viral fate in patients. Additional viral pharmacokinetic and pharmacodynamic variables include analysis of intratumoral viral replication and immune infiltrates by immunohistochemistry and circulating immune cell status. In multi-institutional trials, it may be optimal to use centralized testing to ensure reproducibility.
Resistance Mechanisms
One of the most fascinating features of OV therapy is the battle between the virus and the host, which is vital in determining the therapeutic outcome. The major resistance mechanisms in OV therapy result from to the ability of the host to rapidly shut down viral replication. Table 2 ; full list in eTable 2 in the Supplement). There is representation from multiple countries across 4 continents, with most trials being conducted in the United States. These trials have been almost exclusively performed in adults, with studies in young adults and pediatric patients just beginning. 73 Most trials are early-phase, dose-finding, and exploratory studies, although increasing numbers of late-phase trials are anticipated. Trials increasingly incorporate viral pharmacokinetics and pharmacodynamics, and a consistent feature is monitoring of the immune response to virus and tumor. Few viruses in the present trials express human transgenes. Based on encouraging preclinical data, numerous combination studies are under way using small molecules and chemotherapy. As described below, most trials involve combination therapy with immune checkpoint blockade.
Immune Therapy OV Combinations There is presently a clear opportunity to investigate the impact of combining immunostimulatory OVs with immune checkpoint blockade in cancers, effectively accelerating the antitumor immune response while removing the barriers that may otherwise impair T-cell-mediated tumor killing. Indeed, talimogene laherparepvec is now in a clinical trial in combination with ipilimumab. Currently, pembrolizumab (anti-PD1) and ipilimumab are being tested in combination with talimogene laherparepvec, Cavatak, and Reolysin (eTable 2 in the Supplement). These combinations may allow greater response rates in immune-sensitive tumors, such as melanoma, and may render checkpoint inhibitor-resistant tumors more sensitive to treatment. The number of potential combinations of immune therapies is enormous, and an important question is whether preclinical studies can accurately predict which of these combinations will be the most efficacious in humans. 84 Overall, further work is required to evaluate the possible direct effects of each type of OV on immune checkpoint mechanisms and determine the best combinations for future trials. agents. Because these viruses have co-evolved with humans, they provide unique ways to stimulate immune attack, which may overcome the formidable interactions of tumor cells with the immune system. Improved viruses, in terms of tumor selectivity and potency, and optimized combinations with other immune therapies may lead to further advances in patient outcomes. Given the increasing array of OVs in development, as well as other immune stimulatory agents, the challenge in the field will be to successfully identify the OVs and combinations that will be the most effective for patients, particularly those with tumors that are resistant to other therapies. 
Coxsackie Virus
CAVATAK
Intravesical instillation+ MMC
Phase I Viralytics
Non-muscle invasive bladder cancer Safety/tolerability UK
CAVATAK
Intratumoral + ipilimumab
Phase I Viralytics
Advanced melanoma Safety/tolerability Effiicacy USA Abbreviations AA -anaplastic astrocytoma, AO -anaplastic oligodendroglioma, GBM -glioblastoma multiforme, GC -gliomatosis cerebri, GSgliosarcoma, MTD -maximum tolerated dose, IT -intratumoral, IV -intravenous, QoL -quality of life, CPA -cyclophosphamide, FOLFIRI (irinotecan, fluorouracil, leucovorin). Viral PK/PD, viral pharmacokinetics/dynamics, including replication, shedding, replication, DexDexamethasone. Immune response includes anti-viral immunity, Immune response -includes measurement of circulating immune cells, TILS, serum cytokines, intratumoral PD1 expressing cells, neutralizing antobodies. MMC -mitomycin C, Efficacy -includes overall response rate, progression fee survival, overall survival, durable response rate, time to progression, radiographic response.
